Jump to ContentJump to Main Navigation
Show Summary Details
In This Section

Seminars in Cardiovascular Medicine

The Journal of Lithuanian Heart Association

1 Issue per year

Open Access
Online
ISSN
1822-7767
See all formats and pricing
In This Section

Almanac 2013: heart failure

Andrew L. Clark
  • Corresponding author
  • Academic Cardiology, Hull York Medical School, Castle Hill Hospital, Castle Road, Cottingham
  • Email:
Published Online: 2014-01-29 | DOI: https://doi.org/10.2478/semcard-2013-0007
  • [1] National Heart Failure Audit April 2011-March 2012. National Centre for Cardiovascular Prevention and Outcomes, University College London, 2012. https://www.ucl.ac.uk/nicor/audits/heartfailure/additionalfiles/pdfs/annualreports/annual12.pdf

  • [2] Takeda A, Taylor SJ, Taylor RS, et al. Clinical service organisation for heart failure. Cochrane Database Syst Rev 2012;9:CD002752.

  • [3] Holland R, Battersby J, Harvey I, et al. Systematic review of multidisciplinary interventions in heart failure. Heart 2005;91:899-906.

  • [4] Thomas R, Huntley A, Mann M, et al. Specialist clinics for reducing emergency admissions in patients with heart failure: a systematic review and meta-analysis of randomised controlled trials. Heart 2013;99:233-9.

  • [5] National Institute for Health and Care Excellence.Chronic heart failure. Clinical guideline 108. London, 2010.

  • [6] Al-Mohammad A, Mant J. The diagnosis and management of chronic heart failure: review following the publication of the NICE guidelines. Heart 2011;97:411-16. [Crossref]

  • [7] National Institute for Health and Care Excellence.Chronic heart failure quality standard: QS9. London, 2011.

  • [8] Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 2013;6:606-19. [Crossref]

  • [9] Mostofsky E, Rice MS, Levitan EB, et al. Habitual coffee consumption and risk of heart failure: a dose-response meta-analysis. Circ Heart Fail 2012;5:401-5. [Crossref]

  • [10] McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847.

  • [11] Shah AS, Langrish JP, Nair H, et al. Global association of air pollution and heart failure: a systematic review and meta-analysis. Lancet. Published Online First: 9 July 2013. doi:10.1016/S0140-6736(08)61345-8 [Crossref]

  • [12] Aliti GB, Rabelo ER, Clausell N, et al. Aggressive fluid and sodium restriction in acute decompensated heart failure a randomized clinical trial. JAMA Intern Med 2013;173:1058-64.

  • [13] Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007;49:675-83. [Crossref]

  • [14] Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre RELAX AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009;373:1429-39.

  • [15] Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013;381:29-39.

  • [16] http://www.novartis.com/newsroom/media-releases/en/2013/1711047.shtml (accessed 2 Jul 2013).

  • [17] Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012;380:1387-95.

  • [18] Cleland JG, Clark AL. Heart failure-does it matter whether LVEF is reduced? Lancet 2012;80:1363-5.

  • [19] Packer M, Colucci W, Fisher L, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail 2013;1:103-11.

  • [20] Goldacre B. Are clinical trial data shared sufficiently today? No. BMJ 2013;347:f1880.

  • [21] Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-85.

  • [22] Böhm M, Borer J, Ford I, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study.Clin Res Cardiol 2013;102:11-22.

  • [23] National Institute for Health and Care Excellence.Ivabradine in chronic heart failure. 2012. http://www.nice.org.uk/TA267

  • [24] Hardman SM. Ivabradine in heart failure: NICE guidance.Heart. Published Online First: 18 June 2013. http://heart.bmj.com/content/early/2013/06/17/heartjnl-2012-303490.full.pdf+html?sid=29e1ec6a-5827-4d48-95ac-87be0a60b7c6

  • [25] Castagno D, Petrie MC, Claggett B, et al. Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. Eur Heart J 2012;33:1137-41. [Crossref]

  • [26] Chemaly ER, Hajjar RJ, Lipskaia L. Molecular targets of current and prospective heart failure therapies. Heart 2013;99:992-1003.

  • [27] McMurray JJ, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008;1:17-24.

  • [28] Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204-13.

  • [29] Gheorghiade M, Albaghdadi M, Zannad F, et al. Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). Eur J Heart Fail 2011;13:100-6. [Crossref]

  • [30] Gheorghiade M, Böhm M, Greene SJ, et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 2013;309:1125-35.

  • [31] Krum H, Massie B, Abraham WT, et al. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. Eur J Heart Fail 2011;13:107-14.

  • [32] McMurray JJ, Abraham WT, Dickstein K, et al. ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail 2012;14:341-3. [Crossref]

  • [33] Phelan D, Thavendiranathan P, Collier P, et al. Aldosterone antagonists improve ejection fraction and functional capacity independently of functional class: a meta-analysis of randomised controlled trials. Heart 2012;98:1693-700. [Crossref]

  • [34] Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.JAMA 2013;309:781-91.

  • [35] Pandor A, Gomersall T, Stevens JW, et al. Remote monitoring after recent hospital discharge in patients with heart failure: a systematic review and network meta-analysis. Heart. Published Online First: 16 May2013. http://heart.bmj.com/content/early/2013/05/15/heartjnl-2013-303811.full.pdf+html?sid=25776cbc-1e08-4e6f-abc1-638828de7d98

  • [36] Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008;359:1009-17.

  • [37] Moss AJ, Schuger C, Beck CA, et al. Reduction in inappropriate therapy and mortality through ICD programming.N Engl J Med 2012;367:2275-83.

  • [38] Deyell MW, Qi A, Chakrabarti S, et al. Prognostic impact of inappropriate defibrillator shocks in a population cohort.Heart 2013;99:1250-5.

  • [39] Hawkins NM, Petrie MC, Burgess MI, et al. Selecting patients for cardiac resynchronization therapy: the fallacy of echocardiographic dyssynchrony. J Am Coll Cardiol 2009;53:1944-59.

  • [40] Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure.N Engl J Med 2010;363:2385-95.

  • [41] Witte KK. Cardiac resynchronisation therapy for chronic heart failure: predicting and measuring ‘response’. Heart 2013;99:293-4.

  • [42] Mullens W, Verga T, Grimm RA, et al. Persistent hemodynamic benefits of cardiac resynchronization therapy with disease progression in advanced heart failure. J Am Coll Cardiol 2009;53:600-7.

  • [43] Verbrugge FH, Dupont M, Vercammen J, et al. Time from emerging heart failure symptoms to cardiac resynchronisation therapy: impact on clinical response. Heart 2013;99:314-19.

  • [44] Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Circulation. Published Online First: 5 June2013. http://circ.ahajournals.org/content/early/2013/06/03/CIR.0b013e31829e8776.long

  • [45] Curtis AB, Worley SJ, Adamson PB, et al. Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block (BLOCK HF) Trial Investigators.Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med 2013;368:1585-93.

  • [46] Schwartz PJ. Vagal stimulation for the treatment of heart failure: a translational success story. Heart 2012;98:1687-9. [Crossref] [PubMed]

  • [47] Schwartz PJ, De Ferrari GM, Sanzo A, et al. Long term vagal stimulation in patients with advanced heart failure: first experience in man. Eur J Heart Fail 2008;10:884-91. [Crossref]

  • [48] Hauptman PJ, Schwartz PJ, Gold MR, et al. Rationale and study design of the increase of vagal tone in heart failure study: INOVATE-HF. Am Heart J 2012;163:954-62.

  • [49] Banner NR, Bonser RS, Clark AL, et al. UK guidelines for referral and assessment of adults for heart transplantation.Heart 2011;97:1520-7.

  • [50] Fröhlich GM, Holzmeister J, Hübler M, et al. Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation.Heart 2013;99:1158-65.

  • [51] Makkar RR, Smith RR, Cheng K, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 2012;379:895-904.

About the article

Published Online: 2014-01-29

Published in Print: 2013-12-01



Citation Information: Seminars in Cardiovascular Medicine, ISSN (Online) 1822-7767, DOI: https://doi.org/10.2478/semcard-2013-0007. Export Citation

This content is open access.

Comments (0)

Please log in or register to comment.
Log in